dBRD9-A
Chemical Name: 2-((2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)(methyl)amino)-N-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)acetamide
Purity: ≥98%
Biological Activity
dBRD9-A is a potent BRD9 Degrader (PROTAC®). Selectively binds BRD9 and elicits near complete degradation of BRD9 at nanomolar concentrations. Inhibits growth of synovial sarcoma cells in vitro and tumor progression in a synovial sarcoma xenograft mouse model. BRD9 antibody validated for Simple Western™ (automated Western) instruments and Western Blot also available: Catalog # NBP3-14730.PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license
Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Additional Information
Background References
-
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
Brien et al.
Elife, 2018;7:e41305
Product Datasheets
Reconstitution Calculator
Molarity Calculator
Citation for dBRD9-A
The citations listed below are publications that use Tocris products. Selected citations for dBRD9-A include:
1 Citation: Showing 1 - 1
-
SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma.
Authors: Nazar Et al.
Nat Genet 2022;54:861-873
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for dBRD9-A
There are currently no reviews for this product. Be the first to review dBRD9-A and earn rewards!
Have you used dBRD9-A?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image